灰指甲市場規模、佔有率和成長分析（按類型、治療方法和地區）- 產業預測 2025-2032

2023 年全球灰指甲市場規模價值 53 億美元，預計將從 2024 年的 55.4 億美元成長到 2032 年的 78.8 億美元，預測期間（2025-2032 年）的複合年成長率為 4.5%。

全球灰指甲市場專注於灰指甲的診斷和治療，隨著人們對指甲健康認知的不斷提高以及老齡化、糖尿病和免疫力缺乏等疾病的日益流行，預計該市場將大幅成長。該市場包括外用和口服抗真菌藥物、指甲油以及用於雷射治療和指甲剝落的先進醫療設備等各種產品。主要企業包括製藥公司、醫療設備製造商和醫療保健提供者，他們致力於研發、產品發布和策略聯盟以擴大市場佔有率。該市場的關鍵地區包括北美、歐洲和亞太地區，反映出對旨在改善全身健康的有效治療和創新解決方案的強烈需求。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 次要和資料資料
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態及展望

• 市場概況
• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024 年）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析

灰指甲市場規模（按類型和複合年成長率）（2025-2032）

• 市場概況
• 遠端灰指甲
• 白色表淺性灰指甲
• 近端甲下甲灰指甲
• 其他

灰指甲市場規模（按治療方法和複合年成長率） (2025-2032)

• 市場概況
• 口服
• 局部的
• 其他

灰指甲市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前 5 家公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採用的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024 年）
• 主要企業簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場分析市場佔有率
  • 收益與前一年同期比較（2022-2024 年）

主要企業簡介

• Bausch Health Companies Inc.（Canada）
• GSK plc（UK）
• Abbott（US）
• Pfizer Inc.（US）
• Bayer AG（Germany）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Cipla Inc.（India）
• Merck & Co., Inc.（US）
• Novartis AG（Switzerland）
• Sun Pharmaceutical Industries Ltd.（India）
• Sanofi（France）
• Johnson & Johnson（US）
• Eli Lilly and Company（US）
• Mylan NV（US）
• Galderma SA（Switzerland）
• Valeant Pharmaceuticals International, Inc.（Canada）
• Sandoz International GmbH（Germany）
• Lupin Limited（India）
• Dr. Reddy's Laboratories Ltd.（India）
• Aurobindo Pharma Limited（India）

結論和建議

Global Onychomycosis Market size was valued at USD 5.3 billion in 2023 and is poised to grow from USD 5.54 billion in 2024 to USD 7.88 billion by 2032, growing at a CAGR of 4.5% during the forecast period (2025-2032).

The global onychomycosis market, centered on the diagnosis and treatment of nail fungal infections, is poised for significant growth due to rising awareness of nail health and a growing prevalence of conditions such as aging, diabetes, and immune deficiencies. This market encompasses a variety of products including topical and oral antifungal medications, nail lacquers, and advanced medical devices for laser therapy and nail debridement. Key players include pharmaceutical firms, medical device manufacturers, and healthcare providers who are engaging in R&D, product launches, and strategic partnerships to enhance their market share. Major regions for this market include North America, Europe, and Asia Pacific, reflecting a strong demand for effective treatments and innovative solutions aimed at promoting overall well-being.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Market Segmental Analysis

Global Onychomycosis Market is segmented by Type, Treatment and region. Based on Type, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis and others. Based on Treatment, the market is segmented into Oral, Topical and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Onychomycosis Market

The global onychomycosis market is significantly driven by the rising prevalence of various risk factors, including the growing rates of diabetes, an aging population, compromised immune systems, and instances of nail trauma. As these factors elevate the vulnerability to fungal infections, they result in an expanding demographic of patients seeking diagnosis and treatment for onychomycosis. Consequently, this surge in affected individuals underscores the increasing demand for effective therapeutic solutions, thereby propelling market growth. The correlation between these risk factors and the incidence of onychomycosis highlights the urgent need for improved awareness, prevention, and treatment options in the healthcare sector.

Restraints in the Global Onychomycosis Market

One of the significant constraints in the global onychomycosis market is the potential side effects and limitations linked to existing treatment modalities. Although oral antifungal drugs are recognized for their efficacy, they come with risks of systemic side effects, necessitating close monitoring of patients. Furthermore, topical treatments often struggle with effectiveness in addressing severe or deeply entrenched infections. These challenges can impede market expansion and complicate the delivery of safe and effective treatment alternatives for individuals affected by onychomycosis, ultimately affecting patient outcomes and clinician confidence in treatment strategies.

Market Trends of the Global Onychomycosis Market

The global onychomycosis market is witnessing a significant trend towards the development of innovative and convenient treatment solutions, driven by an increasing demand for therapies that prioritize efficacy, shorter treatment durations, and greater patient adherence. Market participants are actively investing in research and development to introduce novel options such as advanced topical formulations, specialized lacquers, and cutting-edge laser therapies. This shift not only enhances treatment effectiveness but also reflects a broader commitment within the industry to address the evolving needs of patients suffering from fungal nail infections, ultimately aiming to improve clinical outcomes and quality of life for affected individuals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Onychomycosis Market Size by Type & CAGR (2025-2032)

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• others

Global Onychomycosis Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Oral
• Topical
• others

Global Onychomycosis Market Size & CAGR (2025-2032)

• North America (Type, Treatment)
  • US
  • Canada
• Europe (Type, Treatment)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Treatment)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Treatment)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Treatment)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Bausch Health Companies Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Inc. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma S.A. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International, Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz International GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations